NERV Company Profile and Key Details
Minerva Neurosciences
Price Chart
Stock Price Today
Minerva Neurosciences, Inc. (NERV) stock declined over -1.71%, trading at $4.02 on NASDAQ, down from the previous close of $4.09. The stock opened at $4.12, fluctuating between $3.97 and $4.24 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 30, 2026 | 4.12 | 4.24 | 3.97 | 4.02 | 87.46K |
| Jul 29, 2026 | 4.28 | 4.30 | 3.95 | 4.09 | 163.5K |
| Jul 28, 2026 | 4.19 | 4.38 | 3.95 | 4.28 | 199.22K |
| Jul 27, 2026 | 4.09 | 4.28 | 3.95 | 4.21 | 168.09K |
| Jul 24, 2026 | 4.48 | 4.48 | 4.00 | 4.04 | 172.53K |
| Jul 23, 2026 | 4.34 | 4.68 | 4.27 | 4.45 | 135.63K |
| Jul 22, 2026 | 4.47 | 4.55 | 4.16 | 4.43 | 159.26K |
| Jul 21, 2026 | 4.36 | 4.54 | 4.15 | 4.48 | 228.49K |
| Jul 20, 2026 | 4.27 | 4.46 | 4.09 | 4.37 | 183.14K |
| Jul 17, 2026 | 4.13 | 4.41 | 4.01 | 4.27 | 169.91K |
| Jul 16, 2026 | 4.28 | 4.50 | 4.09 | 4.21 | 166.35K |
| Jul 15, 2026 | 4.03 | 4.35 | 3.94 | 4.32 | 186.92K |
| Jul 14, 2026 | 4.29 | 4.34 | 4.01 | 4.02 | 169.83K |
| Jul 13, 2026 | 4.68 | 4.68 | 4.27 | 4.27 | 160.82K |
| Jul 10, 2026 | 4.70 | 4.85 | 4.25 | 4.72 | 235.01K |
| Jul 09, 2026 | 4.63 | 4.77 | 4.53 | 4.72 | 195.39K |
| Jul 08, 2026 | 4.69 | 4.72 | 4.56 | 4.62 | 166.23K |
| Jul 07, 2026 | 4.92 | 4.95 | 4.59 | 4.77 | 188.42K |
| Jul 06, 2026 | 5.07 | 5.10 | 4.72 | 4.92 | 239.55K |
| Jul 02, 2026 | 5.18 | 5.36 | 4.73 | 5.10 | 286.9K |
Contact Details
About Company
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Company Information
| Employees | 7 |
| Beta | -0.18 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Executive Chairman & Chief Executive Officer
Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA
Pres
Mr. Frederick W. Ahlholm CPA, CPA
Senior Vice President, Chief Financial Officer & Sec.
Mr. Joseph Reilly
Senior Vice President & Chief Operating Officer
Mr. William B. Boni
Vice President of Investor Relations & Corporation Communications
Prof. Michael Davidson M.D.
Chief Medical Officer
Dr. Ramana Kuchibhatla Ph.D.
Senior Vice President and Head of R&D
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep